zentaris.com (AEZS) Price to Earnings Ratio

Corporate emblem and logo of Aeterna Zentaris Inc. (AEZS)

Aeterna Zentaris (AEZS) relies on stable authority within a niche medical segment, where physician trust is coupled with expectations of new breakthroughs. Ownership of active patents and licenses guarantees regular payments, transforming the product portfolio into a sustainable profit generator. The confirmed price history on the chart shows that the PE dynamics are -1.00. However, a limited pipeline of developments and the struggle for government funding create risks when facing more powerful market behemoths.

Zentaris (AEZS) Price to Earnings Ratio: for the period 07/04/2022 - 08/10/2024

Comprehensive metric breakdowns and analytics for Aeterna Zentaris Inc. (AEZS)

- price and consensus price forecast:
Stock Price zentaris.com|AEZS - Price Target Chart
- market capitalization details:
Market Value Aeterna Zentaris Inc|AEZS - Enterprise Value
- book capitalization information:
Net Assets per Share Aeterna Zentaris|AEZS - Company Net Assets|Market Capitalization to Net Assets zentaris.com|AEZS - Company Total Assets
- debt and solvency information:
Debt to Capital Aeterna Zentaris|AEZS - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Aeterna Zentaris Inc.|AEZS - Company Total Debt|Debt to Net Assets Ratio Zentaris|AEZS - Company Long-Term Debt|Current Liabilities Aeterna Zentaris|Intermediate Coverage Ratio zentaris.com
- earnings and market multiples details:
AEZS - Net Profit|Projected Future Earnings Aeterna Zentaris|AEZS - Price to Earnings Ratio|Future Price to Earnings Multiple zentaris.com|AEZS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Aeterna Zentaris Inc|AEZS - Operating profit EBITDA|Net earnings per share (EPS TTM) Aeterna Zentaris|AEZS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth zentaris.com|AEZS - Earnings growth in current year|Expected net earnings per share growth next year Aeterna Zentaris
- issuer revenue and sales details:
AEZS - Company Sales|Company Projected Revenue Volume Aeterna Zentaris|AEZS - P/S Multiple|Market Cap to Future Revenue Ratio Zentaris
General company analysis:Aeterna Zentaris Inc - AEZS
Original product of zentaris.com

Aeterna Zentaris (AEZS) is investing in a team of biologists to develop innovative endocrine drugs. The P/E ratio reflects the payback period via net profit, comparing the market value of shares with the business's actual earnings. The current value of -1.00 allows for an assessment of the premium paid for the future success of R&D projects. It is critical for investors to correlate this signal with fundamental expectations. By analyzing the historical P/E levels of Aeterna Zentaris (AEZS), one can determine the asset's fair value point.

Analysis of competing companies

P/E Multiple Vertex Pharmaceuticals Incorporated|Price to Earnings Ratio Alnylam Inc. (ALNY)|Price to Earnings Ratio INSM (Insmed Inc)|P/E Multiple UTHR (unither.com)|Business Payback Period BioMarin (BMRN)|BBIO: Price to Earnings Ratio|Market Cap to Earnings bgm.ltd|COGT: P/E Multiple|Market Cap to Earnings Xeris Biopharma Inc (XERS)|KROS (Keros Therapeutics, Inc.) - P/E Multiple|Price to Earnings Multiple ARCT (Arcturus Therapeutics Holdings Inc.)|Price to Earnings Ratio ETON (Eton Pharmaceuticals, Inc.)|KMDA (Kamada Ltd) - Company Value to Net Income|Price to Earnings Ratio Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona) - Market Cap to Net Income|Mereo BioPharma Group plc - P/E Multiple|PLX - P/E Multiple|PLRX: P/E Multiple|Applied Therapeutics Inc. (APLT) - P/E Multiple|Price to Earnings Ratio Rein Therapeutics, Inc.|GELS: Company Value to Net Income|Price to Earnings Ratio Aytu BioPharma Inc (AYTU)|Price to Earnings Ratio Chemomab Therapeutics Ltd. CMMB|P/E Multiple SRXH (SRx Health Solutions Inc)|P/E Multiple Polyrizon Ltd PLRZ|Cyclo Therapeutics, Inc - P/E Multiple|Business Payback Period Inozyme Pharma INZY|RPHM: P/E Multiple|Market Cap to Earnings cosciensbio.com (CSCI)